Botanix Pharmaceuticals Limited
OTC: BXPHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Howie McKibbon
- Employees
- 11
- Headquarters
- West Perth, Australia
- IPO year
- 2019
- Market cap
- $48.1M
- Website
- https://www.botanixpharma.com
Loading BXPHF…
Loading profile data…Frequently asked questions about BXPHF
What does Botanix Pharmaceuticals Limited (BXPHF) do?
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 150...
Where does BXPHF trade?
Botanix Pharmaceuticals Limited (BXPHF) trades on the Other OTC.
What sector is BXPHF in?
Botanix Pharmaceuticals Limited (BXPHF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Botanix Pharmaceuticals Limited?
Howie McKibbon is the chief executive officer of Botanix Pharmaceuticals Limited (BXPHF).
Where is Botanix Pharmaceuticals Limited headquartered?
Botanix Pharmaceuticals Limited is headquartered in Australia.
Does BXPHF pay a dividend?
Botanix Pharmaceuticals Limited (BXPHF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BXPHF go public?
Botanix Pharmaceuticals Limited (BXPHF) completed its initial public offering in 2019.